Skip to main navigation

Investor Relations

  • Who We Are
    • Management
    • Board of Directors
  • Our Focus
    • Dismutase Mimetics
    • Reducing Oral Mucositis
    • Aiming to Increase Efficacy of Radiation Therapy
  • Our Pipeline
    • Avasopasem (GC4419)
    • Rucosopasem (GC4711)
    • Clinical Trials
    • Key Publications
  • Investors
    • IR Home
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Shareholder Services
  • Contact Us

Press Releases

Press Releases
Aug 09, 2022
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
View HTML
PDF Version
Jun 29, 2022
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
View HTML
PDF Version
Jun 02, 2022
Galera to Present at Jefferies Healthcare Conference
View HTML
PDF Version
May 26, 2022
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
View HTML
PDF Version
May 16, 2022
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
View HTML
PDF Version
May 16, 2022
Galera Announces Plan to Submit Avasopasem NDA by Year End
View HTML
PDF Version
May 02, 2022
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
View HTML
PDF Version
Apr 27, 2022
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
View HTML
PDF Version
Mar 10, 2022
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
View HTML
PDF Version
Jan 06, 2022
Galera to Present at H.C. Wainwright BioConnect Conference
View HTML
PDF Version
results

Investor Relations - Horizontal

IR Home
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Shareholder Services

Tools

Day High:
Day Low:
Volume:
Jul 18, 2022 12:35 AM EDT

Data Provided by Refinitiv.
Minimum 15 minutes delayed.

© Copyright 2022 Galera Therapeutics
Website Design & Development Graphic Beans
Privacy Policy – Terms of Use – Compassionate Use Policy

LinkedIn